Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?
Teerlink
John R
JR
School of Medicine, University of California, and the Section of Cardiology, Veterans Affairs Medical Center, San Francisco, CA 94121-1545, USA.
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000077300:Bosentan; D002986:Clinical Trials as Topic; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013841:Thiazepines / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D018377:Neurotransmitter Agents; D011725:Pyridines; D013449:Sulfonamides; D013841:Thiazepines; C106266:omapatrilat; D004656:Enalapril; D008666:Metalloendopeptidases; D000077300:Bosentan